## Ugo Moretti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/52035/publications.pdf

Version: 2024-02-01

471061 454577 35 991 17 30 citations h-index g-index papers 40 40 40 1250 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. British Journal of Clinical Pharmacology, 1999, 48, 839-846.	1.1	140
2	COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. Drug Safety, 2021, 44, 1247-1269.	1.4	85
3	Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 533-542.	1.1	83
4	Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. Targeted Oncology, 2019, 14, 205-221.	1.7	72
5	Liver injury with novel oral anticoagulants: assessing postâ€marketing reports in the US Food and Drug Administration adverse event reporting system. British Journal of Clinical Pharmacology, 2015, 80, 285-293.	1.1	66
6	The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?. Drug Safety, 2019, 42, 347-363.	1.4	65
7	Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drugâ€induced liver injury case–control study in Italy. British Journal of Clinical Pharmacology, 2016, 82, 238-248.	1.1	59
8	Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe. PLoS ONE, 2015, 10, e0119551.	1.1	49
9	Patient-Reported Safety Information: A Renaissance of Pharmacovigilance?. Drug Safety, 2016, 39, 883-890.	1.4	43
10	Adverse Drug Reactions Related to the Use of NSAIDs with a Focus on Nimesulide. Drug Safety, 2001, 24, 1081-1090.	1.4	39
11	Pediatric drug safety surveillance in Italian pharmacovigilance network: an overview of adverse drug reactions in the years 2001 – 2012. Expert Opinion on Drug Safety, 2014, 13, 9-20.	1.0	36
12	Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibaseÂ $^{\circ}$ . Expert Opinion on Drug Safety, 2019, 18, 1099-1108.	1.0	28
13	The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project. Drug Safety, 2016, 39, 59-68.	1.4	25
14	Mining approximate temporal functional dependencies with pure temporal grouping in clinical databases. Computers in Biology and Medicine, 2015, 62, 306-324.	3.9	21
15	From narrative descriptions to MedDRA: automagically encoding adverse drug reactions. Journal of Biomedical Informatics, 2018, 84, 184-199.	2.5	21
16	Photosensitivity with Angiotensin II Receptor Blockers: A Retrospective Study Using Data from VigiBase®. Drug Safety, 2015, 38, 889-894.	1.4	20
17	Assessment of adverse reactions to $\hat{l}_{\pm}$ -lipoic acid containing dietary supplements through spontaneous reporting systems. Clinical Nutrition, 2021, 40, 1176-1185.	2.3	18
18	Identifying and Characterizing Serious Adverse Drug Reactions Associated With Drug-Drug Interactions in a Spontaneous Reporting Database. Frontiers in Pharmacology, 2020, 11, 622862.	1.6	16

#	Article	IF	CITATIONS
19	Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project. BioDrugs, 2021, 35, 749-764.	2.2	16
20	Consultancy and surveillance of post-immunisation adverse events in the Veneto region of Italy for 1992-2008. Hum Vaccin, 2011, 7, 234-239.	2.4	13
21	Adverse drug reactions associated with off-label use of ketorolac, with particular focus on elderly patients. An analysis of the Italian pharmacovigilance database and a population based study. Expert Opinion on Drug Safety, 2016, 15, 61-67.	1.0	11
22	Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines, 2021, 9, 19.	2.1	11
23	Automagically Encoding Adverse Drug Reactions in MedDRA. , 2015, , .		10
24	Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system. Expert Opinion on Drug Safety, 2021, 20, 1421-1431.	1.0	9
25	COVID-19 Patient Management in Outpatient Setting: A Population-Based Study from Southern Italy. Journal of Clinical Medicine, 2022, 11, 51.	1.0	8
26	Assessment of the Risk of Fragrance Allergy in the General Population. Drug Safety, 2008, 31, 440-443.	1.4	7
27	No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibase. Expert Review of Vaccines, 2018, 17, 363-381.	2.0	7
28	Cosmetovigilance. Drug Safety, 2008, 31, 437-439.	1.4	5
29	Spontaneous reporting of adverse drug reactions in an Italian region: Six years of analysis and observations. Pharmacoepidemiology and Drug Safety, 1995, 4, 129-135.	0.9	3
30	Ten years of vaccinovigilance in Italy: an overview of the pharmacovigilance data from 2008 to 2017. Scientific Reports, 2020, 10, 14122.	1.6	2
31	Central nervous system-active drug abused and overdose in children: a worldwide exploratory study using the WHO pharmacovigilance database. European Journal of Pediatrics, 2019, 178, 161-172.	1.3	1
32	Statin-Associated Psychiatric Adverse Events. Drug Safety, 2008, 31, 1115-1123.	1.4	1
33	Reply-Letter to the editor - The valuable support of spontaneous reporting systems in exploring safety profile of dietary supplements. Clinical Nutrition, 2020, 39, 3854-3855.	2.3	1
34	Italian monitoring registries: a tool for a safer use of innovative drugs? Data from the national pharmacovigilance system. Expert Opinion on Drug Safety, 2016, 15, 69-75.	1.0	0
35	Authors' Reply to Alain Braillon's Comment on "The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project― Drug Safety, 2016, 39, 367-368.	1.4	O